EZH2 and neoplasm: On the other hand, EZH2 silencing upregulates tumor-suppressor factors such as p15, p21, p27 and miRNA-218 that can in turn suppress the progression of lung and gastric cancers and enhance their sensitivity to cisplatin chemotherapy [244].